Reneo Pharmaceuticals (RPHM) Stock Analysis

What Reneo Pharmaceuticals does

Reneo Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to creating therapies for individuals suffering from uncommon inherited mitochondrial disorders. The company's lead candidate, REN001, functions as a selective peroxisome proliferator-activated receptor delta agonist. This compound is currently undergoing Phase IIb clinical trials for patients with primary mitochondrial myopathies. Additionally, REN001 is being assessed in Phase 1b clinical trials for those diagnosed with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Founded in 2014, Reneo Pharmaceuticals' headquarters are located in San Diego, California.

Key metrics

ETFs linked to RPHM

Broad-market and Healthcare sector ETFs an investor holding Reneo Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RPHM fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Reneo Pharmaceuticals?

Reneo Pharmaceuticals trades under the ticker RPHM on NASDAQ.

Which exchange is RPHM listed on?

RPHM is listed on NASDAQ.

What sector does Reneo Pharmaceuticals operate in?

Reneo Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RPHM in a portfolio?

PortView shows RPHM's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.